Australia's TGA reiterates: Nicotine pouches are prescription drugs in Australia, and unapproved products pose safety risks.

Aug.08.2025
Australia's TGA reiterates: Nicotine pouches are prescription drugs in Australia, and unapproved products pose safety risks.
Illegal sale of nicotine pouches in Australia is on the rise, posing health risks and legal consequences.

Key points:

 

·Illegal sales on the rise: The illegal advertising and online sales of nicotine pouches in Australia have increased, with many products coming from overseas and not approved by the Therapeutic Goods Administration (TGA). 

·Legal restrictions: Nicotine pouches are considered prescription drugs in Australia and cannot be sold in retail stores or advertised. 

·Health risks: Nicotine pouches contain high concentrations of nicotine, which can lead to addiction, brain development issues, and various side effects. 

·Legal consequences: Those who violate the law may face up to 5 years in prison and a fine of up to 1.32 million Australian dollars (approximately 860,000 US dollars). 

·Consumer advice: Before purchasing nicotine pouches, make sure to have a prescription or written authorization, and consult a doctor or pharmacist.

 


 

According to the official website of the Therapeutic Goods Administration (TGA) on August 7th, illegal advertisements and online sales of nicotine pouches in Australia have increased, with many of these products being imported from overseas. It is important to note that nicotine pouches are considered prescription drugs in Australia and currently no nicotine pouch products have been approved by the TGA. This means that nicotine pouch products have not undergone safety, quality, and efficacy testing in Australia.

 

Nicotine pouches are small pouches placed between the lips and gums, typically containing varying strengths of nicotine, as well as other ingredients such as sweeteners and flavors. They are often marketed as a "smoke-free" or "tobacco-free" alternative to e-cigarettes. However, there is little evidence to suggest that they are effective in helping people quit smoking or reduce their dependence on nicotine.

 

According to Australian law, nicotine pouches are classified as prescription medications. This means that they:

 

It cannot be sold in retail stores or tobacco shops; advertising is not allowed; it cannot be imported or sold without approval from the TGA or a valid written authorization or prescription from an Australian healthcare practitioner.

 

Some states may have additional restrictions. For example, in South Australia, nicotine pouches are banned under new tobacco and e-cigarette legislation.

 

Violating the law could lead to serious consequences. According to the 1989 Therapeutic Goods Act, significant fines, including up to 5 years imprisonment, a maximum fine of 1.32 million Australian dollars (approximately 860,000 US dollars), or both, may be imposed for illegal advertising and supply activities. Additionally, further fines may be imposed under state and territory medicines and poisons laws.

 

Nicotine pouches can be dangerous. Some nicotine pouches contain high concentrations of nicotine, which may lead to side effects. They are not produced according to Australian standards, and their safety has not been inspected.

 

Nicotine is highly addictive, especially for young people. It may interfere with brain development, affecting memory, learning, and attention.

 

Side effects associated with nicotine pouches include: increased heart rate and high blood pressure; nausea, dizziness, and headaches; mouth ulcers.

 

Some products may not list nicotine on the ingredients label. The lack of clear ingredient information on the label could potentially lead to delayed treatment if the product is ingested, which is especially dangerous for children. Furthermore, mislabeled products are considered counterfeit and should not be imported or supplied under any circumstances.

 

Before purchasing nicotine pouches, make sure you have a prescription or written authorization, and meet all legal requirements. Discuss with your doctor or pharmacist how to properly obtain unapproved medications. Read information from the Therapeutic Goods Administration (TGA) regarding unapproved therapeutic goods.

 

The Therapeutic Goods Administration (TGA) has approved nicotine replacement therapies, including patches, sprays, and lozenges. Unlike nicotine pouches, these products meet Australian quality, safety, and effectiveness standards. They are available for purchase at pharmacies and supermarkets.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris Japan adds “Electric Purple” to IQOS ILUMA i range, expands to convenience stores from Feb. 3
Philip Morris Japan adds “Electric Purple” to IQOS ILUMA i range, expands to convenience stores from Feb. 3
Philip Morris Japan (PMJ) said on Jan. 29 it has introduced “Electric Purple” as a new standard color option for its IQOS ILUMA i heated tobacco device lineup, covering three models with prices unchanged. The new color will be available from Jan. 29 via the company’s official online and store channels, with sales expanding to convenience stores and some tobacco retailers from Feb. 3.
Jan.29 by 2FIRSTS.ai
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
China has for the first time issued clear regulatory rules for nicotine pouches and other oral nicotine products, formally classifying them under the tobacco monopoly alongside cigarettes and tobacco, ending a long-standing legal grey zone and laying the regulatory groundwork for their potential domestic launch.
Jan.09 by Alan Zhao | 2Firsts Perspectives
Two Florida Bills Move: One Restricts Vape Advertising, Another Rewrites Cigarette Tax Treatment for Heated Tobacco
Two Florida Bills Move: One Restricts Vape Advertising, Another Rewrites Cigarette Tax Treatment for Heated Tobacco
The Florida Senate Industries Committee advance SB 980, the “Florida Age-Gate Act,” which would restrict advertising, promotion, and open displays of certain nicotine dispensing devices that lack FDA marketing authorization, with escalating penalties. Separately, the Florida House Ways and Means Committee advance HB 377, which would exclude heated tobacco products from being taxed like cigarettes.
Jan.28 by 2FIRSTS.ai
UK South East Seized 3.1M Illegal Vapes Since 2021 as Crackdown Intensifies
UK South East Seized 3.1M Illegal Vapes Since 2021 as Crackdown Intensifies
Illegal vape seizures in the UK South East have risen sharply over the past five years, with 2023 marking the high point. While single-use vapes were banned from sale in June 2025, enforcement teams say disposable products remain in circulation, fueling renewed calls for licensing and stronger enforcement funding.
Jan.23 by 2FIRSTS.ai
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
IQOS Partners with Mexico’s Zamna Festival; PMI Says Adult User Base Tops 140,000
IQOS Partners with Mexico’s Zamna Festival; PMI Says Adult User Base Tops 140,000
Philip Morris International (PMI) said IQOS, via its “IQOS Curious X” platform, has entered a global partnership with the Zamna music festival in Tulum, Mexico, with the collaboration making its on-site debut during Zamna 2026 and targeting adult nicotine users. PMI said IQOS has more than 34 million users worldwide, while the number of adult consumers in Mexico has surpassed 140,000.
Jan.15 by 2FIRSTS.ai